Results 51 to 60 of about 2,386,530 (346)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

Frontiers in Immunology, 2017
Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis.
Christodoulos Filippis, Katharina Arens, Gaetan Aime Noubissi Nzeteu, Gabriele Reichmann, Zoe Waibler, Peter Crauwels, Ger van Zandbergen, Ger van Zandbergen   +7 more
doaj   +1 more source

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition

Diagnostics, 2021
Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT).
Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong   +3 more
doaj   +1 more source

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Tzu Chi Medical Journal, 2023
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj   +1 more source

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source

Autophagy is activated and involved in cell death with participation of cathepsins during stress-induced microspore embryogenesis in barley [PDF]

, 2018
Microspores are reprogrammed towards embryogenesis by stress. Many microspores die after this stress, limiting the efficiency of microspore embryogenesis. Autophagy is a degradation pathway that plays critical roles in stress response and cell death.
Berenguer, Eduardo, Bárány, Ivett, Crespo González, José Luis, Pérez Pérez, Yolanda, Risueño, M. Carmen   +4 more
core   +1 more source

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Pakistan Armed Forces Medical Journal, 2021
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim   +3 more
doaj   +1 more source

M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s [PDF]

, 2019
Background Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single agents have a lack of ...
Dang, Nanmao, Gao, Fei, Huang, Dong, Huang, Jun-Yong, Jowsey, Paul, Li, Jianquan, Lightowlers, Robert N., Martinez-Lopez, Nuria   +7 more
core   +1 more source

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

JTO Clinical and Research Reports, 2022
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance ...
Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD   +20 more
doaj   +1 more source

Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]

, 2012
A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin, Bak, Peter, Barnkob, Mike Stein, Chen, Jianzhu, Higham, Eileen M., Wittrup, Karl Dane   +5 more
core   +1 more source